MapLight Therapeutics said it is pausing preclinical and discovery efforts and reallocating resources to advance its lead candidate, ML-007C-MA, for schizophrenia and Alzheimer’s disease psychosis. The company positioned the pivot as a way to concentrate capital and execution on moving the primary program toward late development. The update follows earlier setbacks in parts of MapLight’s pipeline that prompted investors to scrutinize how much parallel experimentation the company could sustain. MapLight also highlighted changes in its strategic posture, effectively reducing spend outside the core clinical asset. Separately in the same news stream, ADC Therapeutics’ decision-making around Zynlonta was referenced, reinforcing the broader pattern of biotech portfolio tightening when clinical timelines lengthen and risk tolerance narrows.